Astrazeneca PLC (AZN) News

Astrazeneca PLC (AZN)

Today's Latest Price: $53.74 USD

0.96 (1.82%)

Updated Dec 4 4:00pm

Add AZN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

Filter AZN News Items

AZN News Results

Event/Time Symbol Company News Detail Start End Change POWR Rating
Loading, please wait...

Latest AZN News From Around the Web

Below are the latest news stories about Astrazeneca Plc that investors may wish to consider to help them evaluate AZN as an investment opportunity.

AstraZeneca’s Farxiga nabs accelerated review in U.S. for kidney disease

The FDA has granted Breakthrough Therapy Designation to AstraZeneca’s (AZN) Farxiga for the treatment of patients with chronic kidney disease, with and without type-2 diabetes.Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the...

Seeking Alpha | October 2, 2020

Study of AstraZeneca COVID-19 vaccine resumes in Japan

Following a review of safety data by an independent committee, a Phase 1/2 clinical trial evaluating AstraZeneca's (AZN) COVID-19 vaccine candidate, AZD1222, has resumed in Japan following earlier restarts in the U.K., Brazil, South Africa and India.The U.S. study has yet to resume....

Seeking Alpha | October 2, 2020

IMV: Covid Vaccine Play Plus Diversified

Canadian biotech IMV Inc. (IMV) can rely on government and industry financial support totaling $3.58 million to continue the development of its experimental vaccine against the new coronavirus. IMV has a market cap of $306 million. This support is essential in enabling the Nova Scotia-based company to perform clinical trials...

Chetan Woodun on Seeking Alpha | October 2, 2020

Shattuck Labs Starts $100 Million IPO Plan

Quick Take Shattuck Labs (STTK) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The firm is a clinical stage biopharma advancing programs to treat ovarian cancer and other cancers. STTK has produced intriguing early stage safety and efficacy results....

Donovan Jones on Seeking Alpha | October 2, 2020

Canada to Begin Review of AstraZeneca COVID-19 Vaccine Amid Immunization Skepticism

No summary available.

UrduPoint | October 2, 2020

AstraZeneca Working With Russian Partners for Delivery of COVID-19 Vaccine- Representative

No summary available.

UrduPoint | October 2, 2020

News24.com | Leading Covid-19 vaccine trial resumes in Japan but not US

Trials on the coronavirus vaccine developed by AstraZeneca and Oxford University have resumed in Japan but not the United States, where the pharmaceutical giant is working with regulators, a statement released said.

News24 | October 2, 2020

Canada is reviewing its first COVID-19 vaccine application. Here’s what that means

AstraZeneca has applied for Canadian regulatory approval for the so-called Oxford vaccine, becoming the first company to do so. But don’t expect a finished vaccine just yet

The Star | October 2, 2020

AZN Stock Slightly Down, AstraZeneca Resumes Vaccine Trials in Japan

Following the earlier suspension, AstraZeneca (AZN) disclosed that it received authorization to resume COVID-19 vaccine trial in Japan.

Coinspeaker | October 2, 2020

Moderna, Pfizer & BioNTech, and AstraZeneca and the University of Oxford's COVID-19 Vaccine Trials are Entering the Final Stage of Development

DUBLIN, Oct. 2, 2020 /PRNewswire/ -- ResearchAndMarkets.com published a new article on the vaccine industry "COVID-19 Vaccine Trials are Entering the Final Stage of Development" Johnson & Johnson has begun final stage testing of its COVID-19 vaccine candidate. The company will trial the…

PR Newswire | October 2, 2020



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6047 seconds.